Research Notes Preclinical studies demonstrate that 5-Amino-1MQ increases NAD+ availability leading to enhanced mitochondrial efficiency and ATP production
Fewer systemic side-effects compared to hGH Because AOD 9604 does not significantly elevate IGF-1 or impair glucose/insulin regulation (in trials), it may carry lower risk of some growth hormone-associated adverse effects
Semaglutide, by contrast, offers: Faster and more significant weight loss Comprehensive benefits for individuals with or without diabetes Established safety and effectiveness in large-scale clinical trials If achieving substantial weight loss is your primary goal, Semaglutide is likely the better choice
Those who are medically supervised, have no contraindications (good metabolic/insulin health, no untreated severe disease), and willing to combine peptide therapy with diet, exercise, sleep, and recovery